Global Health IPO will open for subscription from 03 November 2022. the company aims for an issue size of ₹2,205.57 Cr through this IPO.
Global Health Limited
The company is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India in terms of bed capacity and operating revenues amongst the players that operate in the North and East regions of India, as of and for the financial year ended 31 March 2022, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.
Under the “Medanta” brand, it has a network of five hospitals currently in operation (Gurugram, Indore, Ranchi, Lucknow, and Patna) and one hospital (Noida), which is under construction. As of 30 June 2022, it provides healthcare services in over 30 medical specialties and engages over 1,300 doctors led by experienced department heads, spanning an area of 4.7 million sq. ft., its operational hospitals have 2,467 installed beds.
Medanta Hospital is founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon. He has been awarded the prestigious Padma Bhushan and the Padma Shri, the third and fourth-highest civilian awards in India, and the BC Roy award. Its hospital at Gurugram was featured in the list of the world’s best-specialized hospitals for cardiology and neurology in 2022 and the list of world’s best-specialized hospitals for cardiology in 2021 by Newsweek and was awarded the ‘Best Multi-Speciality Hospital – National’ at the ‘Economic Times Healthcare Awards 2021’ and ranked as the best multispecialty private hospital in North India by ‘The Week’ in 2021.
Basic details about the company
| Full name | Global Health Limited |
| Sector | Healthcare |
| Industry | Hospital & Healthcare Services |
| Company Website | https://www.medanta.org/ |
Major competitive strengths
- Large-scale hospitals with world-class infrastructure, high-end medical equipment, and technology.
- Focus on under-served areas with dense populations and presence in the top or capital cities of large states (NCR, Lucknow, and Patna).
- Leading tertiary and quaternary care provider in India, well recognized for clinical expertise in particular in dealing with complicated cases.
- Experienced senior management team with strong institutional shareholder support.
- Focus on Clinical Research and Academics.
- Experienced senior management team with strong institutional shareholder support.
- Growth opportunities in existing facilities and diversification into new services, including digital health.
Objects of the Issue
- Repayment/prepayment of borrowings, in full or part, of the Subsidiaries, GHPPL and MHPL.
- General corporate purposes.
Dates to remember
| IPO Opening date | 03 November 2022 |
| IPO Closing | 07 November 2022 |
| Basis of Allotment | 11 November 2022 |
| Initiation Refund | 14 November 2022 |
| Credit to Demat Account | 15 November 2022 |
| Listing Date | 16 November 2022 |
Global Health IPO Details
| IPO Date | Nov 3, 2022 to Nov 7, 2022 |
| Face Value | ₹2 per share |
| Price | ₹319 to ₹336 per share |
| Lot Size | 44 Shares |
| Issue Size | [.] shares of ₹2 (aggregating up to ₹2,205.57 Cr) |
| Fresh Issue | [.] shares of ₹2 (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 50,761,000 shares of ₹2 (aggregating up to ₹1,705.57 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Global Health IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 44 | ₹14,784 |
| Retail (Max) | 13 | 572 | ₹192,192 |
| S-HNI (Min) | 14 | 616 | ₹206,976 |
| B-HNI (Min) | 68 | 2,992 | ₹1,005,312 |
Reservation Details
| QIB Shares Offered | 50% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 35% |
Global Health Financial Performance
| FY 2020 | FY 2021 | FY 2022 | Q1 FY 2023 | |
| Revenue | 1,500.4 | 1,446.7 | 2,166.6 | 617.2 |
| Expenses | 1,480.4 | 1,445.7 | 1,925.3 | 539.5 |
| Net income | 36.3 | 28.8 | 196.2 | 58.7 |
| Margin (%) | 2.42 | 1.99 | 9.06 | 9.51 |
Medanta Valuations & Margins
| FY 2020 | FY 2021 | FY 2022 | |
| EPS | 1.44 | 1.14 | 7.77 |
| PE ratio | – | – | 41.05 – 43.24 |
| RONW (%) | 2.69 | 2.08 | 12.14 |
| NAV | 54.70 | 55.76 | 63.82 |
| ROCE (%) | 5.90 | 5.00 | 16.30 |
| Debt/Equity | 0.50 | 0.50 | 0.50 |
Company Promoters
- Dr. Naresh Trehan
Lead Manager(s)
- Kotak Mahindra Capital Company Limited
- Credit Suisse Securities (India) Private Limited
- Jefferies India Private Limited
- JM Financial Consultants Private Limited
Global Health IPO Registrar
KFIN TECHNOLOGIES LIMITED
Selenium Tower B, Plot No – 31 & 32,
Financial District, Nanakramguda,
Serilingampally, Hyderabad Rangareddi,
500 032, Telangana, India
Phone: +91 40 6716 2222
Email: globalhealth.ipo@kfintech.com
Website: www.kfintech.com
Global Health Contact Details
GLOBAL HEALTH LIMITED
Medanta – The Medicity,
Sector – 38, Gurgaon,
Haryana 122 001
Phone: +91 124 483 4060
Email: compliance@medanta.org
Website: www.medanta.org
Global Health IPO Allotment Status
Global Health IPO allotment will be available on KFin Technologies’ website.
Click on this link to get allotment status.
Final thoughts
Global Health IPO is going to hit Dalal street soon. applying for IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make wise decisions.
Happy Investing
